A61K 2039/5254
Avirulent or attenuated
Official title: {avirulent or attenuated}
A61K2039/5254 (Avirulent or attenuated) appears on 1,736 US grants and 2,128 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,736
- Published applications
- 2,128
- Assignees
- 859
- Inventors
- 3,549
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 14 | 0 |
| 1977 | 9 | 0 |
| 1978 | 5 | 0 |
| 1979 | 4 | 0 |
| 1980 | 5 | 0 |
| 1981 | 6 | 0 |
| 1982 | 10 | 0 |
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 10 | 0 |
| 1986 | 9 | 0 |
| 1987 | 10 | 0 |
| 1988 | 6 | 0 |
| 1989 | 5 | 0 |
| 1990 | 6 | 0 |
| 1991 | 13 | 0 |
| 1992 | 9 | 0 |
| 1993 | 8 | 0 |
| 1994 | 6 | 0 |
| 1995 | 8 | 0 |
| 1996 | 12 | 0 |
| 1997 | 21 | 0 |
| 1998 | 35 | 0 |
| 1999 | 28 | 0 |
| 2000 | 31 | 0 |
| 2001 | 33 | 9 |
| 2002 | 23 | 29 |
| 2003 | 37 | 63 |
| 2004 | 27 | 79 |
| 2005 | 26 | 72 |
| 2006 | 29 | 49 |
| 2007 | 46 | 78 |
| 2008 | 45 | 80 |
| 2009 | 53 | 92 |
| 2010 | 59 | 114 |
| 2011 | 57 | 90 |
| 2012 | 51 | 103 |
| 2013 | 53 | 81 |
| 2014 | 90 | 85 |
| 2015 | 57 | 74 |
| 2016 | 67 | 99 |
| 2017 | 84 | 101 |
| 2018 | 88 | 104 |
| 2019 | 94 | 119 |
| 2020 | 82 | 105 |
| 2021 | 81 | 95 |
| 2022 | 76 | 94 |
| 2023 | 51 | 102 |
| 2024 | 58 | 97 |
| 2025 | 53 | 74 |
| 2026 | 43 | 40 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Ambient temperature lipid particle storage systems and methods29 Sep 2026US 12,746,281 B2Ambient Biosciences, Inc.
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Compositions and methods for stabilizing flaviviruses with improved formulations15 Sep 2026US 12,734,230 B2Takeda Vaccines, Inc.
- Coronavirus vaccines compositions and method of using same8 Sep 2026US 12,728,159 B2Loyola University of Chicago
- Inactivation of pathogens using metal-based coordination complexes, and methods and compositions for treating and preventing microbial and/or viral infections1 Sep 2026US 12,721,854 B2Theralase Technologies, Inc.
- Natural attenuated strain of infectious laryngotracheitis virus with good safety and good immunogenicity and use thereof8 Oct 2026US 2026/0306619 A1Institute of Animal Husbandry and Veterinary Medicine, Fujian Academy of Agricultural Sciences
- Dengue virus serotype-specific modulation of t cell responses8 Oct 2026US 2026/0306621 A1The United States Government as represented by the Department of Veterans Affairs
- Canine parvovirus10 Sep 2026US 2026/0263590 A1Intervet Inc.
- A vaccine for protecting a pregnant swine against african swine fever3 Sep 2026US 2026/0256902 A1Intervet Inc.
- Formulations and uses thereof20 Aug 2026US 2026/0240766 A1Sartorius Albumedix Limited
Most cited
By later US patents
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Method of inducing an immune response with a live Venezuelan Equine Encephalitis virus expressing a heterologous immunogen123US 5,643,576 AThe University of North Carolina at Chapel Hill · 1997
- European vaccine strains of the porcine reproductive and respiratory syndrome virus110US 5,925,359 AAkzo Nobel N. V. · 1999
- Zika virus RNA vaccines108US 10,124,055 B2ModernaTX, Inc. · 2018